Financial terms were not disclosed, although Nordion will leave an estimated US$18m in the company.
Best Medical has acquired all of MDS Nordion, with the exception of the TheraSphere business, which develops liver cancer therapeutics.
The firm bought another Nordion company, Ottawa-based Theratronics, four years ago.
Nordion made a decision in the 2010 financial year to restructure or exit this business, stating that it wanted to reduce complexity, manage costs and focus on growing areas of the business.
The 55 employees at MDS Nordion will transfer to Best Medical, which will also acquire the Belgian production facilities.
Nordion expects the transaction to be completed in the next few months.
Nordion sells Belgian operation
Best Medical to buy MDS Nordion, terms not revealed
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Investing in the future of healthcare: from diagnostics innovation to scientific talent pipelines
Read moreStrategic UK investment in next-generation cancer diagnostics and cardiovascular research training is accelerating innovation, reducing barriers to adoption and building the multidisciplinary talent needed to deliver long-term improvements in patient outcomes and life sciences growth
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
Upcoming event
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Investing in the future of healthcare: from diagnostics innovation to scientific talent pipelines
Strategic UK investment in next-generation cancer diagnostics and cardiovascular research training is accelerating innovation, reducing barriers to adoption and building the multidisciplinary talent needed to deliver long-term improvements in patient outcomes and life sciences growth
Research & Development
Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus
Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables